BridgeBio Pharma BBIO Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's total liabilities?
- BridgeBio Pharma (BBIO) reported total liabilities of $3.64B in Q1 2026.
- How has BridgeBio Pharma's total liabilities changed year-over-year?
- BridgeBio Pharma's total liabilities increased by 44.4% year-over-year, from $2.52B to $3.64B.
- What is the long-term trend for BridgeBio Pharma's total liabilities?
- Over 5 years (2020 to 2025), BridgeBio Pharma's total liabilities has grown at a 38.3% compound annual growth rate (CAGR), from $595.7M to $3.01B.
- What does total liabilities mean?
- The total amount of money the company owes to all creditors and stakeholders.
- How do you interpret total liabilities?
- A rising trend relative to assets may indicate increasing financial leverage and potential solvency risks.
- How does total liabilities compare across companies?
- Standardized across all industries; essential for calculating debt-to-equity ratios.